The CEO of embattled drug maker Mylan testified before a House panel last week that one of the main reasons the company had to hike up the prices on its signature EpiPens from $100 to $600 is the "more than one billion dollars" it has invested in the past decade "to enhance the product and make it more available."
So, as Congress has been trying to figure out the company's business model, a medical technologies expert and a doctor have been physically taking apart Mylan's famed auto injectors to find out exactly how — and where — that money was spent.
More from NBC:
Seychelles police release cause of death for Annie, Robin Korkki
Hoboken Crash: Feds begin analyzing recorder data, will interview engineer
Alicia Machado responds to Trump: 'I will continue standing'
After a Seattle doctor cut EpiPens from before Mylan's upgrades and after open, NBC News sent versions of the epinephrine auto injectors to a medical technology consulting firm. Despite seeing safety and graphics upgrades, both found the devices shared a similar "core."